Segment Information

9 Months Ended

Sep. 30, 2018

Note 17 ― Segment Information

See Note 1 for a description of the Company’s reporting segments.

In the Company’s segment disclosures, we present “operating revenues,” defined as total revenues excluding realized investment results and certain net investment income described in special items below. Beginning in 2018, certain realized investment results from the Company's equity method joint ventures in the Global Supplemental Benefits segment are also excluded due to the potential increased volatility in investment results after adopting ASU 2016-01. Investment gains or losses are managed based on factors largely unrelated to the underlying business purpose of each segment and are not indicative of the underlying performance of the Company’s core business operations, so they are excluded from operating revenues.

The Company uses “adjusted income (loss) from operations” as its principal financial measure of segment operating performance because management believes it best reflects the underlying results of core business operations and permits analysis of trends in underlying revenue, expenses and profitability. Adjusted income from operations is defined as shareholders’ net income (loss) excluding after-adjustments for realized investment gains and losses, amortization of other acquired intangible assets and special items. Income or expense amounts that are excluded from adjusted income from operations because they are not indicative of underlying performance or the responsibility of operating segment management include:

Realized investment results, including changes in market values of financial instruments between balance sheet dates, as well as gains and losses associated with invested asset sales. As discussed above, beginning in 2018, certain realized investment results from the Company's equity method joint ventures in the Global Supplemental Benefits segment are also excluded.
Amortization of other intangible assets related to costs incurred for acquisitions
Special items, if any, that management believes are not representative of the underlying results of operations due to the nature or size of these matters. Further context about these items is provided in the footnotes listed in the following tables.

	Three Months Ended
	September 30, 2018				September 30, 2017
(In millions)	Before-tax		After-tax		Before-tax		After-tax
Transaction-related costs
- Net investment income - see Note 3	$	(13)	$	(10)	$	-	$	-
- Other operating expenses - see Note 3		141		118		9		6
Total transaction-related costs		128		108		9		6
Charges associated with litigation matters - see Note 16		45		35		-		-
Charges associated with U.S. tax reform
- Other operating expenses - see Note 15		2		2		-		-
- Tax (benefit) - see Note 15		-		(7)		-		-
Total charges (benefits) associated with U.S. tax reform		2		(5)		-		-
Debt extinguishment costs - See Note 5		-		-		321		209
Total impact from special items	$	175	$	138	$	330	$	215











	Nine Months Ended
	September 30, 2018				September 30, 2017
(In millions)	Before-tax		After-tax		Before-tax		After-tax
Transaction-related costs
- Net investment income - see Note 3	$	(13)	$	(10)	$	-	$	-
- Other operating expenses - see Note 3		331		277		88		8
Total transaction-related costs		318		267		88		8
Charges associated with litigation matters - see Note 16		45		35		-		-
Charges associated with U.S. tax reform
- Other operating expenses - see Note 15		2		2		-		-
- Tax (benefit) - see Note 15		-		(7)		-		-
Total charges (benefits) associated with U.S. tax reform		2		(5)		-		-
Debt extinguishment costs - See Note 5		-		-		321		209
Long-term care guaranty fund assessment - see Note 16(D)		-		-		129		83
Total impact from special items	$	365	$	297	$	538	$	300

Summarized segment financial information was as follows:

(In millions)	Global Health Care		Global Supplemental Benefits		Group Disability and Life		Other Operations		Corporate		Total
Three Months Ended September 30, 2018
Premiums, fees and other revenues and mail order pharmacy revenues⁽¹⁾	$	8,995	$	1,055	$	1,032	$	33	$	(13)	$	11,102
Net investment income		122		37		89		87		20		355
Less net realized investment (losses) from equity method subsidiaries⁽²⁾		-		(1)		-		-		-		(1)
Less special item (transaction-related costs)		-		-		-		-		13		13
Operating revenues	$	9,117	$	1,093	$	1,121	$	120	$	(6)	$	11,445
Total revenues	$	9,121	$	1,093	$	1,124	$	112	$	7	$	11,457
Shareholders' net income (loss)	$	750	$	80	$	106	$	9	$	(173)	$	772
After-tax adjustments to reconcile to adjusted income from operations
Net realized investment (gains) losses⁽²⁾		(4)		-		(4)		8		(1)		(1)
Amortization of other acquired intangible assets, net		32		4		-		-		-		36
Special items
Transaction-related costs		-		-		-		-		108		108
Charges associated with litigation matters		35		-		-		-		-		35
U.S. tax reform		(9)		9		(2)		(1)		(2)		(5)
Total special items		26		9		(2)		(1)		106		138
Adjusted income (loss) from operations	$	804	$	93	$	100	$	16	$	(68)	$	945

Three Months Ended September 30, 2017
Premiums, fees and other revenues and mail order pharmacy revenues⁽¹⁾	$	8,087	$	954	$	1,015	$	29	$	(11)	$	10,074
Net investment income		89		31		84		86		8		298
Operating revenues	$	8,176	$	985	$	1,099	$	115	$	(3)	$	10,372
Total revenues	$	8,251	$	985	$	1,136	$	120	$	(3)	$	10,489
Shareholders' net income (loss)	$	610	$	105	$	97	$	18	$	(270)	$	560
After-tax adjustments to reconcile to adjusted income from operations
Net realized investment (gains)		(47)		-		(24)		(4)		-		(75)
Amortization of other acquired intangible assets, net		12		4		-		-		-		16
Special items
Transaction-related costs		-		-		-		-		6		6
Debt extinguishment costs		-		-		-		-		209		209
Total special items		-		-		-		-		215		215
Adjusted income (loss) from operations	$	575	$	109	$	73	$	14	$	(55)	$	716

(1) Includes the Company's share of the earnings of its joint ventures in China and India in the Global Supplemental Benefits segment.
(2) Beginning in 2018, the Company's share of certain realized investment results of equity method joint ventures in the Global Supplemental Benefits segment (reported in fees and other revenues) is excluded from operating revenues and adjusted income from operations.

(In millions)	Global Health Care		Global Supplemental Benefits		Group Disability and Life		Other Operations		Corporate		Total

Nine Months Ended September 30, 2018
Premiums, fees and other revenues and mail order pharmacy revenues⁽¹⁾	$	26,994	$	3,171	$	3,089	$	97	$	(37)	$	33,314
Net investment income including special items		362		107		275		260		32		1,036
Less net realized investment (losses) on equity method subsidiaries⁽²⁾		-		(23)		-		-		-		(23)
Less special item (transaction related costs)		-		-		-		-		13		13
Operating revenues	$	27,356	$	3,301	$	3,364	$	357	$	(18)	$	34,360
Total revenues	$	27,345	$	3,268	$	3,356	$	351	$	(6)	$	34,314
Shareholders' net income (loss)	$	2,372	$	271	$	267	$	57	$	(474)	$	2,493
After-tax adjustments to reconcile to adjusted income from operations
Net realized investment losses⁽²⁾		7		28		5		5		1		46
Amortization of other acquired intangible assets		59		15		-		-		-		74
Special items
Transaction-related costs		-		-		-		-		267		267
Charges associated with litigation matters		35		-		-		-		-		35
U.S. tax reform		(9)		9		(2)		(1)		(2)		(5)
Total special items		26		9		(2)		(1)		265		297
Adjusted income (loss) from operations	$	2,464	$	323	$	270	$	61	$	(208)	$	2,910


Nine Months Ended September 30, 2017
Premiums, fees and other revenues and mail order pharmacy revenues⁽¹⁾	$	24,382	$	2,759	$	3,070	$	89	$	(35)	$	30,265
Net investment income		273		90		262		260		24		909
Operating revenues	$	24,655	$	2,849	$	3,332	$	349	$	(11)	$	31,174
Total revenues	$	24,788	$	2,861	$	3,399	$	351	$	(11)	$	31,388
Shareholders' net income (loss)	$	1,753	$	283	$	253	$	55	$	(373)	$	1,971
After-tax adjustments to reconcile to adjusted income from operations
Net realized investment (gains)		(85)		(9)		(44)		(2)		-		(140)
Amortization of other acquired intangible assets		40		14		-		-		-		54
Special items
Transaction-related costs		-		-		-		-		8		8
Debt extinguishment costs		-		-		-		-		209		209
Long-term care guaranty fund assessment		68		-		15		-		-		83
Total special items		68		-		15		-		217		300
Adjusted income (loss) from operations	$	1,776	$	288	$	224	$	53	$	(156)	$	2,185

(1) Includes the Company's share of the earnings of its joint ventures in China and India in the Global Supplemental Benefits segment.
(2) Beginning in 2018, the Company's share of certain realized investment results of equity method joint ventures in the Global Supplemental Benefits segment (reported in fees and other revenues) is excluded from operating revenues and adjusted income from operations.

Revenue from external customers includes premiums, fees and other revenues and mail order pharmacy revenues. The following table presents these revenues by product type for the periods ended September 30:

(In millions)	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Premiums by product (ASC 944 - insurance activities)
Global Health Care
Commercial
Guaranteed cost	$	2,080	$	1,591	$	6,125	$	4,656
Experience-rated		711		737		2,186		2,191
Stop loss		1,010		874		2,983		2,582
International health care		513		484		1,541		1,438
Dental		486		452		1,447		1,334
Other		260		247		777		736
Government
Medicare		1,455		1,324		4,414		4,174
Medicaid		247		253		725		806
Medicare Part D		157		169		574		601
Total Global Health Care		6,919		6,131		20,772		18,518
Disability		507		493		1,522		1,485
Life, Accident and Supplemental Health		1,539		1,428		4,629		4,208
Total premiums from ongoing operations		8,965		8,052		26,923		24,211
Fees (ASC 606 - service activities)
Global Health Care		1,325		1,219		3,984		3,652
Global Supplemental Benefits		7		6		22		18
Group Disability and Life		24		25		74		77
Total fees from ongoing operations		1,356		1,250		4,080		3,747
Mail order pharmacy (ASC 606 - service activities)		747		733		2,222		2,200
Other		34		39		89		107
Total revenues from external customers	$	11,102	$	10,074	$	33,314	$	30,265

Premiums from the Centers for Medicare and Medicaid Services (“CMS”) were 18% of consolidated revenues for the nine months ended September 30, 2018 and 17% for the nine months ended September 30, 2017. These amounts were reported in the Global Health Care segment.